PDX models

In collaboration with local and international partners and taking advantage of its close association with its parent organisation Karaiskakio Foundation, the CSHM is working on establishing xenograft tumour models from patient-derived tumour tissue (PDTT). Patient-derived xenografts are believed to offer relevant predictive insights into clinical outcomes when evaluating the efficacy of novel therapies.